Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading

European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading

MT newswireMT newswire2026/09/22 15:19
11:19 AM EDT, 09/22/2026 (MT Newswires) -- European equities traded in the US as American depositary receipts Tuesday were tracking lower Tuesday morning, declining 0.35% to 1,924.21 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by biotech firms BioNTech (BNTX) and Evaxion (EVAX), which climbed 3.8% and 2.9%, respectively. They were followed by medical device maker EDAP TMS (FOCL) and biopharmaceutical firm Cellectis (CLLS), which advanced 2.2% and 2%, respectively. The decliners from continental Europe were led by telecommunications companies Ericsson (ERIC) and Nokia (NOK), which dropped 4.5% and 3.9% respectively. They were followed by semiconductor company Sequans Communications (SQNS) and lender ING (ING), which fell 2.4% and 1.4% respectively. The gainers from the UK were led by biopharmaceutical company Bicycle Therapeutics (BCYC) and biotech firm Autolus Therapeutics (AUTL), which rose 3.4% and 2.8% respectively. They were followed by biopharmaceutical company Mereo BioPharma Group (MREO) and pharmaceutical company Silence Therapeutics (SLN), which were up 2% and 1.5% respectively. The decliners from the UK and Ireland were led by software firm Endava (DAVA) and biopharmaceutical company Akari Therapeutics (AKTX), which dropped 23% and 3% respectively. They were followed by lenders HSBC (HSBC) and Lloyds Banking Group (LYG), which lost 1.9% and 1.4% respectively.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Guggenheim raises Meta (META.US) target price to $850: Betting on AI agent commercialization

Guggenheim Securities maintained its buy rating for Meta, raising the target price to $850, citing Meta's advantages in the AI field and the potential of the Muse agent. Despite short-term cash flow pressure, the institution believes that Meta's large user base and free strategy will support long-term commercialization, expecting accelerated monetization after 2027.

智通财经•2026/10/15 05:43
Guggenheim raises Meta (META.US) target price to $850: Betting on AI agent commercialization